Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 8/20 | 0.57 |
| ▸ | TARBP2 | Q15633 | 2/20 | 0.52 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.52 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.52 |
| ▸ | PGR | P06401 | 1/20 | 0.52 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.52 |
| ▸ | PDE4A | P27815 | 1/20 | 0.52 |
| ▸ | BLVRB | P30043 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | F11 | P03951 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12316992 | 0.91 | XDH (0.58) | XDHTARBP2ABCC4ABCB11PGR | |
| SCHEMBL2185648 | 0.88 | XDH (0.58) | XDHTARBP2ABCC4ABCB11PGR | |
| SCHEMBL12316983 | 0.85 | XDH (0.57) | XDHTARBP2ABCC4ABCB11PGR | |
| SCHEMBL12316984 | 0.83 | XDH (0.61) | XDHTARBP2ABCC4ABCB11PGR | |
| SCHEMBL438271 | 0.83 | XDH (0.68) | XDHTARBP2ABCC4ABCB11PGR | |
| SCHEMBL12316989 | 0.82 | XDH (0.60) | XDHTARBP2ABCC4ABCB11PGR | |
| SCHEMBL2184262 | 0.82 | XDH (0.62) | XDHTARBP2ABCC4ABCB11PGR | |
| SCHEMBL12316994 | 0.81 | XDH (0.57) | XDHTARBP2ABCC4ABCB11PGR | |
| SCHEMBL12316998 | 0.81 | XDH (0.61) | XDHTARBP2ABCC4ABCB11PGR | |
| SCHEMBL12316978 | 0.81 | XDH (0.66) | XDHTARBP2ABCC4ABCB11PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2343279-B1 | FUSED-RING DERIVATIVE AND MEDICAL APPLICATION OF SAME | KISSEI PHARMACEUTICAL (JP) | 2018-02-28 | — | — | EP | disclosed |
| EP-2343279-B1 | FUSED-RING DERIVATIVE AND MEDICAL APPLICATION OF SAME | KISSEI PHARMACEUTICAL (JP) | 2018-02-28 | — | — | EP | disclosed |
| US-8263622-B2 | Fused-ring derivative and medical application of same | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-09-11 | — | — | US | disclosed |
| US-8263622-B2 | Fused-ring derivative and medical application of same | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-09-11 | — | — | US | disclosed |
| US-8263622-B2 | Fused-ring derivative and medical application of same | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-09-11 | — | — | US | disclosed |
| US-20110207935-A1 | FUSED-RING DERIVATIVE AND MEDICAL APPLICATION OF SAME | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2011-08-25 | — | — | US | disclosed |
| US-20110207935-A1 | FUSED-RING DERIVATIVE AND MEDICAL APPLICATION OF SAME | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2011-08-25 | — | — | US | disclosed |
| US-20110207935-A1 | FUSED-RING DERIVATIVE AND MEDICAL APPLICATION OF SAME | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2011-08-25 | — | — | US | disclosed |
| EP-2343279-A1 | FUSED-RING DERIVATIVE AND MEDICAL APPLICATION OF SAME | Kissei Pharmaceutical Co., Ltd. (JP) | 2011-07-13 | — | — | EP | disclosed |
| EP-2343279-A1 | FUSED-RING DERIVATIVE AND MEDICAL APPLICATION OF SAME | Kissei Pharmaceutical Co., Ltd. (JP) | 2011-07-13 | — | — | EP | disclosed |
| WO-2010044405-A1 | FUSED-RING DERIVATIVE AND MEDICAL APPLICATION OF SAME | キッセイ薬品工業株式会社 (JP) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207935-A1 | FUSED-RING DERIVATIVE AND MEDICAL APPLICATION OF SAME | XDH, OAT, PON1 | XDH 1/4885TARBP2 4436/4885ABCC4 372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.